Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). (Q55006124)
Jump to navigation
Jump to search
scientific article published on 4 January 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). |
scientific article published on 4 January 2017 |
Statements
1 reference
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). (English)
1 reference
Stacy L Moulder
1 reference
Virginia F Borges
1 reference
Tara Baetz
1 reference
Tessa Mcspadden
1 reference
Gina Fernetich
1 reference
Rashmi K Murthy
1 reference
Renae Chavira
1 reference
Kari Guthrie
1 reference
Emma Barrett
1 reference
Stephen K Chia
1 reference
4 January 2017
1 reference
23
1 reference
14
1 reference
3529-3536
1 reference
Identifiers
1 reference